GSK downgraded by Liberum to 'hold' as broker sees better value elsewhere
Liberum downgraded GSK to a ‘hold’ rating from ‘buy’ but raised its target price to 1,700p from 1,630p
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 24 of 38
GlaxoSmithKline offshoot makes HIV breakthrough
The once-a-month jab developed by ViiV Healthcare could replace a daily cocktail of drugs currently prescribed
Investments and investor services
FTSE 100 closes deep in red as Turkey/US worries escalate
Footsie closed down 1.49%, or around 114 points, at 7,497 on the day
Archive
Cineworld investors hope World Cup and hot weather failed to keep customers away in first-half
The day ahead sees Cineworld and Legal & General report their first-half results
GlaxoSmithKline appoints HSBC bean counter on pay, perks package worth up to £3.4mln
Iain Mackay joins the international drugs giant next January
Archive
HSBC will ring down the curtain on the bank's interim reporting season, but other financials also in focus
Aside from HSBC's numbers, Prudential, L&G, Standard Life Aberdeen, and Hargreaves Lansdown are all on the results docket in the coming week
Equiniti shares jump as it expects full-year earnings to reach top end of market forecasts
Equiniti said revenues were boosted by contract renewals and new client wins
FTSE 100 closes higher, boosted by earnings and weaker pound
In London, FTSE 100 added over 38 points to finish at 7,701 - that was up on the week too, marginally - by 0.29%.
FDA committee doesn’t think GSK’s asthma drug can be used to treat COPD as well
Nucala has already been approved to treat asthma patients, but an FDA advisory committee isn't convinced there is enough data to back up GSk's belief that it can help COPD patients as well
GSK unveils new £1.7bn cost-cutting programme as it switches tack on R&D
GSK reckons the changes can save it £400mln a year, while it wants to shift its R&D focus towards immunotherapies and genetics
FTSE 100 closes down as market awaits Trump/Juncker meeting
The UK blue-chip index closed around 50 points lower at 7,658, while FTSE 250 was also down - over 99 points at 20,753
GSK publishes more positive data from HIV trials ahead of Wednesday’s Q2 update
Juluca has been shown to be effective over the course of two years, while GSK’s other two-drug combo supressed the virus in untreated HIV sufferers
Investments and investor services
ITV, GlaxoSmithKline and Indivior to be among the highlights for Wednesday
Among Wednesday's names are ITV, GlaxoSmithKline, Indivior, and Tullow Oil
Archive
FTSE 100 starts week by ending lower as geopolitical woes hit sentiment...again
In London, FTSE 100 shed 23 points to 7,655, while FTSE 250 shed over 155 points at 20,770
GlaxoSmithKline considering business break-up following investor pressure - FT report
The newspaper said GSK’s chairman Philip Hampton has been in discussions with the FTSE 100-listed group’s biggest shareholders about the creation of a standalone pharma and vaccines company in the medium term
Archive
Apres moi le deluge: Flood of blue chip results to dominate in coming week, including BT Group
Over the five sessions in the Week Ahead, around 20% of the FTSE 100 index will report results or issue a trading update, with about half that number due on Thursday alone
Investments and investor services
FTSE 100: Forget Brexit, here’s what we’ll learn from a bumper earnings week
We have a deluge of earnings statements from some of Britain's biggest businesses. Below we discuss the themes likely to emerge from the mid-term reporting season
Archive
ASOS set for a warm weather boost
Thursday will see retailers ASOS and Dunelm to the fore. The former is expected to issue an upbeat statement while the latter will be looking to prove it is not curtains for its growth story.
Archive
High street vs online: Updates from retailers Mark & Spencer and ASOS will provide fuel
Aside from M&S and ASOS, the week ahead will also bring trading updates from the likes of Ocado, Burberry, Barratt Development, Experian, and JD Wetherspoon
GlaxoSmithKline gets double target price lift from Barclays and Deutsche Bank on growth expectations
Analysts at both investment banks expected EPS growth for the FTSE 100 pharma group, while also expecting more clarity from GSK's new head of research and development